Journal article
In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d.
Abstract
SOURCE CITATION: Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245.
Authors
Fuller C; Chagla Z
Journal
Annals of Internal Medicine, Vol. 176, No. 4,
Publisher
American College of Physicians
Publication Date
April 2023
DOI
10.7326/j23-0020
ISSN
1056-8751